MRNA
Moderna, Inc.
Price Chart
Latest Quote
$61.82
| Previous Close | $63.15 |
| Open | $61.63 |
| Day High | $63.28 |
| Day Low | $61.06 |
| Volume | 4,432,996 |
Stock Information
| Shares Outstanding | 396.79M |
| Total Debt | $1.30B |
| Cash Equivalents | $5.21B |
| Revenue | $2.22B |
| Net Income | $-3.19B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $24.53B |
| EPS (TTM) | $-8.14 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $20.62B |
| Sales | $2.22B |
| Income | $-3.19B |
| Book/sh | $18.66 |
| Cash/sh | $13.12 |
| Employees | 5K |
Financial Ratios
| Quick Ratio | 2.23 |
| Current Ratio | 2.41 |
| Debt/Eq | 17.52 |
Returns & Margins
| ROA | -13.09% |
| ROE | -36.56% |
| Gross Margin | -69.89% |
| Operating Margin | -131.10% |
| Profit Margin | -143.55% |
Ownership
| Insider Ownership | 7.31% |
| Institutional Ownership | 78.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -15.03 |
| P/S | 11.02 |
| P/B | 3.31 |
Analyst Data
| Recommendation | hold |
| Target Price | $48.26 |
Technical Indicators
| SMA20 | $68.58 |
| SMA50 | $57.09 |
| SMA200 | $43.39 |
| RSI | 43.60 |
| ATR | 5.0769 |
| Shares Float | 370.07M |
| Short Float | 16.40% |
| Short Ratio | 6.20 |
| Volatility | 0.94 |
| Rel Volume | 0.47 |
Performance History
| Week | -9.45% |
| Month | +11.59% |
| Quarter | +13.06% |
| 6 Months | +52.34% |
| YTD | +100.32% |
| Year | +92.83% |
| 3 Years | -50.91% |
| 5 Years | -73.45% |
| 10 Years | +232.37% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $61.82 | 4,468,505 |
| 2026-07-16 | $63.15 | 5,593,100 |
| 2026-07-15 | $68.28 | 3,427,800 |
| 2026-07-14 | $67.44 | 5,812,300 |
| 2026-07-13 | $67.01 | 8,522,000 |
| 2026-07-10 | $68.27 | 9,176,900 |
| 2026-07-09 | $76.56 | 4,415,000 |
| 2026-07-08 | $73.80 | 6,581,700 |
| 2026-07-07 | $79.77 | 8,688,300 |
| 2026-07-06 | $81.80 | 17,296,900 |
| 2026-07-02 | $79.76 | 14,087,700 |
| 2026-07-01 | $72.50 | 9,275,300 |
| 2026-06-30 | $70.03 | 11,805,900 |
| 2026-06-29 | $69.70 | 8,077,400 |
| 2026-06-26 | $67.27 | 14,456,700 |
| 2026-06-25 | $59.75 | 6,797,400 |
| 2026-06-24 | $60.42 | 11,704,000 |
| 2026-06-23 | $61.00 | 6,814,200 |
| 2026-06-22 | $59.35 | 8,363,500 |
| 2026-06-18 | $63.96 | 24,078,800 |
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?
StockStory âĸ 2026-07-17T16:57:46ZMRNA Advances Cancer Pipeline With New Immunotherapy Study
Zacks âĸ 2026-07-17T14:59:00ZNeglected Quant Safety Trade Makes a Comeback as AI Risks Rise
Bloomberg âĸ 2026-07-17T11:44:19ZArbutus, Sanofi escalate mRNA patent fights; InnoCareâs TYK2 contender advances
BioPharma Dive âĸ 2026-07-17T10:07:25ZABUS Stock On Track For Best Day In About Two Months â Whatâs The Moderna Connection?
Stocktwits âĸ 2026-07-16T18:41:03ZModerna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Proactive âĸ 2026-07-14T17:35:00ZModerna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks âĸ 2026-07-13T21:50:06ZWhat It Means To Hold Moderna Stock In A Crash
Trefis âĸ 2026-07-13T13:12:08ZModerna, Takeda and Capricor on the verge of notching big drug approvals
Pharma Voice âĸ 2026-07-13T08:20:00ZUS Stock Market Today: S&P 500 Futures Rise As Inflation Cools And Earnings Loom
Simply Wall St. âĸ 2026-07-13T08:10:32ZIncome Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $868,000,000 | $1,464,000,000 | $4,693,000,000 | $5,416,000,000 |
| Cost Of Revenue | $868,000,000 | $1,464,000,000 | $4,693,000,000 | $5,416,000,000 |
| Total Revenue | $1,922,000,000 | $3,199,000,000 | $6,754,000,000 | $18,875,000,000 |
| Operating Revenue | $3,304,000,000 | $4,517,000,000 | $8,203,000,000 | $18,435,000,000 |
| Expenses | ||||
| Interest Expense | $10,000,000 | $24,000,000 | $38,000,000 | $29,000,000 |
| Total Expenses | $4,996,000,000 | $7,144,000,000 | $10,993,000,000 | $9,455,000,000 |
| Other Income Expense | $2,000,000 | $-63,000,000 | $-124,000,000 | $-45,000,000 |
| Other Non Operating Income Expenses | $7,000,000 | $-7,000,000 | $-124,000,000 | $-45,000,000 |
| Net Non Operating Interest Income Expense | $304,000,000 | $401,000,000 | $421,000,000 | $200,000,000 |
| Interest Expense Non Operating | $10,000,000 | $24,000,000 | $38,000,000 | $29,000,000 |
| Operating Expense | $4,128,000,000 | $5,680,000,000 | $6,300,000,000 | $4,039,000,000 |
| Other Operating Expenses | $-22,000,000 | $-37,000,000 | $-94,000,000 | $-388,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Net Interest Income | $304,000,000 | $401,000,000 | $421,000,000 | $200,000,000 |
| Interest Income | $314,000,000 | $425,000,000 | $421,000,000 | $200,000,000 |
| Normalized Income | $-2,818,050,000 | $-3,505,714,167 | $-4,714,000,000 | $8,362,000,000 |
| Net Income From Continuing And Discontinued Operation | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Total Operating Income As Reported | $-3,074,000,000 | $-3,945,000,000 | $-4,239,000,000 | $9,420,000,000 |
| Net Income Common Stockholders | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Net Income | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Net Income Including Noncontrolling Interests | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Net Income Continuous Operations | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Pretax Income | $-2,768,000,000 | $-3,607,000,000 | $-3,942,000,000 | $9,575,000,000 |
| Interest Income Non Operating | $314,000,000 | $425,000,000 | $421,000,000 | $200,000,000 |
| Operating Income | $-3,074,000,000 | $-3,945,000,000 | $-4,239,000,000 | $9,420,000,000 |
| Gross Profit | $1,054,000,000 | $1,735,000,000 | $2,061,000,000 | $13,459,000,000 |
| Per Share | ||||
| Diluted EPS | $-7.26 | $-9.28 | $-12.33 | $20.12 |
| Basic EPS | $-7.26 | $-9.28 | $-12.33 | $21.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,050,000 | $-714,167 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,538,000,000 | $-3,338,000,000 | $-3,618,000,000 | $9,768,000,000 |
| Total Unusual Items | $-5,000,000 | $-56,000,000 | $-72,000,000 | $-20,000,000 |
| Total Unusual Items Excluding Goodwill | $-5,000,000 | $-56,000,000 | $-72,000,000 | $-20,000,000 |
| Reconciled Depreciation | $215,000,000 | $189,000,000 | $621,000,000 | $348,000,000 |
| EBITDA (Bullshit earnings) | $-2,543,000,000 | $-3,394,000,000 | $-3,618,000,000 | $9,768,000,000 |
| EBIT | $-2,758,000,000 | $-3,583,000,000 | $-4,239,000,000 | $9,420,000,000 |
| Diluted Average Shares | $389,000,000 | $384,000,000 | $382,000,000 | $416,000,000 |
| Basic Average Shares | $389,000,000 | $384,000,000 | $382,000,000 | $394,000,000 |
| Diluted NI Availto Com Stockholders | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Tax Provision | $54,000,000 | $-46,000,000 | $772,000,000 | $1,213,000,000 |
| Gain On Sale Of Security | $-5,000,000 | $-56,000,000 | $-72,000,000 | $-20,000,000 |
| Research And Development | $3,132,000,000 | $4,543,000,000 | $4,845,000,000 | $3,295,000,000 |
| Selling General And Administration | $1,018,000,000 | $1,174,000,000 | $1,549,000,000 | $1,132,000,000 |
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,553,000,000 | $10,809,000,000 | $13,758,000,000 | $19,123,000,000 |
| Total Assets | $12,338,000,000 | $14,142,000,000 | $18,426,000,000 | $25,858,000,000 |
| Total Non Current Assets | $5,794,000,000 | $6,043,000,000 | $8,101,000,000 | $12,427,000,000 |
| Other Non Current Assets | $160,000,000 | $171,000,000 | $181,000,000 | $946,000,000 |
| Non Current Prepaid Assets | $100,000,000 | $139,000,000 | $342,000,000 | $0 |
| Non Current Deferred Assets | $81,000,000 | $81,000,000 | $81,000,000 | $982,000,000 |
| Non Current Deferred Taxes Assets | $81,000,000 | $81,000,000 | $81,000,000 | $982,000,000 |
| Non Current Accounts Receivable | $161,000,000 | $97,000,000 | - | - |
| Investmentin Financial Assets | $2,336,000,000 | $2,494,000,000 | $4,677,000,000 | $8,318,000,000 |
| Goodwill And Other Intangible Assets | $97,000,000 | $92,000,000 | $96,000,000 | $0 |
| Other Intangible Assets | $45,000,000 | $40,000,000 | $44,000,000 | - |
| Current Assets | $6,544,000,000 | $8,099,000,000 | $10,325,000,000 | $13,431,000,000 |
| Other Current Assets | $45,000,000 | $58,000,000 | $88,000,000 | $44,000,000 |
| Prepaid Assets | $263,000,000 | $307,000,000 | $350,000,000 | $851,000,000 |
| Inventory | $153,000,000 | $117,000,000 | $202,000,000 | $949,000,000 |
| Receivables | $284,000,000 | $592,000,000 | $1,081,000,000 | $1,685,000,000 |
| Other Receivables | $13,000,000 | $58,000,000 | $61,000,000 | $53,000,000 |
| Taxes Receivable | $45,000,000 | $117,000,000 | $69,000,000 | $150,000,000 |
| Accrued Interest Receivable | $42,000,000 | $59,000,000 | $59,000,000 | $61,000,000 |
| Accounts Receivable | $184,000,000 | $358,000,000 | $892,000,000 | $1,385,000,000 |
| Allowance For Doubtful Accounts Receivable | $-184,000,000 | $-340,000,000 | $-692,000,000 | $0 |
| Gross Accounts Receivable | $368,000,000 | $698,000,000 | $1,584,000,000 | $1,385,000,000 |
| Cash Cash Equivalents And Short Term Investments | $5,799,000,000 | $7,025,000,000 | $8,604,000,000 | $9,902,000,000 |
| Cash And Cash Equivalents | $2,595,000,000 | $1,927,000,000 | $2,907,000,000 | $3,205,000,000 |
| Notes Receivable | - | - | $0 | $36,000,000 |
| Hedging Assets Current | - | - | - | - |
| Debt | ||||
| Total Debt | $1,305,000,000 | $747,000,000 | $1,243,000,000 | $1,200,000,000 |
| Long Term Debt And Capital Lease Obligation | $1,263,000,000 | $710,000,000 | $1,218,000,000 | $1,004,000,000 |
| Long Term Debt | $590,000,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $42,000,000 | $37,000,000 | $25,000,000 | $196,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,688,000,000 | $3,241,000,000 | $4,572,000,000 | $6,735,000,000 |
| Total Non Current Liabilities Net Minority Interest | $1,701,000,000 | $1,035,000,000 | $1,557,000,000 | $1,812,000,000 |
| Other Non Current Liabilities | $36,000,000 | $36,000,000 | $21,000,000 | $135,000,000 |
| Tradeand Other Payables Non Current | $249,000,000 | $231,000,000 | $235,000,000 | - |
| Non Current Deferred Liabilities | $153,000,000 | $58,000,000 | $83,000,000 | $673,000,000 |
| Current Liabilities | $1,987,000,000 | $2,206,000,000 | $3,015,000,000 | $4,923,000,000 |
| Other Current Liabilities | $143,000,000 | $184,000,000 | $41,000,000 | $53,000,000 |
| Current Deferred Liabilities | $99,000,000 | $153,000,000 | $568,000,000 | $2,038,000,000 |
| Payables And Accrued Expenses | $774,000,000 | $1,150,000,000 | $1,580,000,000 | $2,446,000,000 |
| Payables | $317,000,000 | $405,000,000 | $583,000,000 | $535,000,000 |
| Accounts Payable | $317,000,000 | $405,000,000 | $520,000,000 | $487,000,000 |
| Total Tax Payable | - | $3,000,000 | $63,000,000 | $48,000,000 |
| Income Tax Payable | - | $3,000,000 | $63,000,000 | $48,000,000 |
| Equity | ||||
| Common Stock Equity | $8,650,000,000 | $10,901,000,000 | $13,854,000,000 | $19,123,000,000 |
| Total Equity Gross Minority Interest | $8,650,000,000 | $10,901,000,000 | $13,854,000,000 | $19,123,000,000 |
| Stockholders Equity | $8,650,000,000 | $10,901,000,000 | $13,854,000,000 | $19,123,000,000 |
| Gains Losses Not Affecting Retained Earnings | $45,000,000 | $-10,000,000 | $-123,000,000 | $-370,000,000 |
| Other Equity Adjustments | $45,000,000 | $-10,000,000 | $-123,000,000 | $-370,000,000 |
| Retained Earnings | $7,223,000,000 | $10,045,000,000 | $13,606,000,000 | $18,320,000,000 |
| Long Term Equity Investment | $6,000,000 | $14,000,000 | $66,000,000 | $42,000,000 |
| Other | ||||
| Ordinary Shares Number | $394,000,000 | $386,000,000 | $382,000,000 | $385,000,000 |
| Share Issued | $394,000,000 | $386,000,000 | $382,000,000 | $385,000,000 |
| Tangible Book Value | $8,553,000,000 | $10,809,000,000 | $13,758,000,000 | $19,123,000,000 |
| Invested Capital | $9,240,000,000 | $10,901,000,000 | $13,854,000,000 | $19,123,000,000 |
| Working Capital | $4,557,000,000 | $5,893,000,000 | $7,310,000,000 | $8,508,000,000 |
| Capital Lease Obligations | $715,000,000 | $747,000,000 | $1,243,000,000 | $1,200,000,000 |
| Total Capitalization | $9,240,000,000 | $10,901,000,000 | $13,854,000,000 | $19,123,000,000 |
| Additional Paid In Capital | $1,382,000,000 | $866,000,000 | $371,000,000 | $1,173,000,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $153,000,000 | $58,000,000 | $83,000,000 | $673,000,000 |
| Long Term Capital Lease Obligation | $673,000,000 | $710,000,000 | $1,218,000,000 | $1,004,000,000 |
| Current Deferred Revenue | $99,000,000 | $153,000,000 | $568,000,000 | $2,038,000,000 |
| Current Capital Lease Obligation | $42,000,000 | $37,000,000 | $25,000,000 | $196,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $420,000,000 | $312,000,000 | $245,000,000 | $190,000,000 |
| Current Provisions | $509,000,000 | $370,000,000 | $556,000,000 | - |
| Current Accrued Expenses | $457,000,000 | $745,000,000 | $997,000,000 | $1,911,000,000 |
| Investments And Advances | $2,342,000,000 | $2,508,000,000 | $4,743,000,000 | $8,360,000,000 |
| Available For Sale Securities | $2,336,000,000 | $2,494,000,000 | $4,677,000,000 | $8,318,000,000 |
| Goodwill | $52,000,000 | $52,000,000 | $52,000,000 | $0 |
| Net PPE | $2,853,000,000 | $2,955,000,000 | $2,658,000,000 | $2,139,000,000 |
| Accumulated Depreciation | $-737,000,000 | $-527,000,000 | $-433,000,000 | $-658,000,000 |
| Gross PPE | $3,590,000,000 | $3,482,000,000 | $3,091,000,000 | $2,797,000,000 |
| Leases | $403,000,000 | $207,000,000 | $522,000,000 | $460,000,000 |
| Construction In Progress | $298,000,000 | $1,057,000,000 | $860,000,000 | $281,000,000 |
| Other Properties | $1,393,000,000 | $1,235,000,000 | $1,587,000,000 | $1,986,000,000 |
| Machinery Furniture Equipment | $235,000,000 | $181,000,000 | $100,000,000 | $59,000,000 |
| Buildings And Improvements | $1,183,000,000 | $743,000,000 | $0 | - |
| Land And Improvements | $78,000,000 | $59,000,000 | $22,000,000 | $11,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $33,000,000 | $28,000,000 | $24,000,000 | $169,000,000 |
| Work In Process | $29,000,000 | $26,000,000 | $15,000,000 | $205,000,000 |
| Raw Materials | $91,000,000 | $63,000,000 | $163,000,000 | $575,000,000 |
| Other Short Term Investments | $3,204,000,000 | $5,098,000,000 | $5,697,000,000 | $6,697,000,000 |
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,075,000,000 | $-4,055,000,000 | $-3,825,000,000 | $4,581,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,873,000,000 | $-3,004,000,000 | $-3,118,000,000 | $4,981,000,000 |
| Cash Flow From Continuing Operating Activities | $-1,873,000,000 | $-3,004,000,000 | $-3,118,000,000 | $4,981,000,000 |
| Operating Gains Losses | $8,000,000 | $52,000,000 | $35,000,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-202,000,000 | $-1,051,000,000 | $-707,000,000 | $-400,000,000 |
| Investing Cash Flow | $1,946,000,000 | $1,949,000,000 | $4,206,000,000 | $-5,176,000,000 |
| Cash Flow From Continuing Investing Activities | $1,946,000,000 | $1,949,000,000 | $4,206,000,000 | $-5,176,000,000 |
| Net Other Investing Changes | - | - | $-23,000,000 | $-40,000,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $35,000,000 | $66,000,000 | $46,000,000 | $65,000,000 |
| Financing Cash Flow | $593,000,000 | $56,000,000 | $-1,377,000,000 | $-3,448,000,000 |
| Cash Flow From Continuing Financing Activities | $593,000,000 | $56,000,000 | $-1,377,000,000 | $-3,448,000,000 |
| Net Other Financing Charges | $-2,000,000 | - | $-1,153,000,000 | - |
| Net Common Stock Issuance | $35,000,000 | $66,000,000 | $46,000,000 | $-3,264,000,000 |
| Common Stock Issuance | $35,000,000 | $66,000,000 | $46,000,000 | $65,000,000 |
| Repurchase Of Capital Stock | - | $0 | $-1,153,000,000 | $-3,329,000,000 |
| Other | ||||
| Repayment Of Debt | $-22,000,000 | $0 | $0 | - |
| Issuance Of Debt | $600,000,000 | $0 | $0 | - |
| Interest Paid Supplemental Data | $10,000,000 | $24,000,000 | $39,000,000 | $25,000,000 |
| Income Tax Paid Supplemental Data | $26,000,000 | $197,000,000 | - | $2,729,000,000 |
| End Cash Position | $2,597,000,000 | $1,929,000,000 | $2,928,000,000 | $3,217,000,000 |
| Beginning Cash Position | $1,929,000,000 | $2,928,000,000 | $3,217,000,000 | $6,860,000,000 |
| Effect Of Exchange Rate Changes | $2,000,000 | $0 | $0 | - |
| Changes In Cash | $666,000,000 | $-999,000,000 | $-289,000,000 | $-3,643,000,000 |
| Net Issuance Payments Of Debt | $560,000,000 | $-10,000,000 | $-270,000,000 | $-184,000,000 |
| Net Long Term Debt Issuance | $560,000,000 | $-10,000,000 | $-270,000,000 | $-184,000,000 |
| Long Term Debt Payments | $-22,000,000 | $0 | $0 | - |
| Long Term Debt Issuance | $600,000,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $2,148,000,000 | $3,000,000,000 | $4,998,000,000 | $-4,736,000,000 |
| Sale Of Investment | $7,916,000,000 | $9,529,000,000 | $8,781,000,000 | $6,699,000,000 |
| Purchase Of Investment | $-5,768,000,000 | $-6,529,000,000 | $-3,783,000,000 | $-11,435,000,000 |
| Net Business Purchase And Sale | $0 | $0 | $-85,000,000 | $0 |
| Purchase Of Business | $0 | $0 | $-85,000,000 | $0 |
| Net Intangibles Purchase And Sale | $-10,000,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-10,000,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-192,000,000 | $-1,051,000,000 | $-707,000,000 | $-400,000,000 |
| Purchase Of PPE | $-192,000,000 | $-1,051,000,000 | $-707,000,000 | $-400,000,000 |
| Change In Working Capital | $233,000,000 | $-78,000,000 | $689,000,000 | $-4,014,000,000 |
| Change In Other Working Capital | $41,000,000 | $-439,000,000 | $-2,060,000,000 | $-4,157,000,000 |
| Change In Other Current Liabilities | $-27,000,000 | $106,000,000 | $639,000,000 | $-754,000,000 |
| Change In Other Current Assets | $38,000,000 | $-53,000,000 | $-605,000,000 | $21,000,000 |
| Change In Payables And Accrued Expense | $-94,000,000 | $-454,000,000 | $-327,000,000 | $852,000,000 |
| Change In Accrued Expense | $-2,000,000 | $-385,000,000 | $-340,000,000 | $612,000,000 |
| Change In Payable | $-92,000,000 | $-69,000,000 | $13,000,000 | $240,000,000 |
| Change In Account Payable | $-92,000,000 | $-69,000,000 | $13,000,000 | $240,000,000 |
| Change In Prepaid Assets | $153,000,000 | $145,000,000 | $1,802,000,000 | $-2,258,000,000 |
| Change In Inventory | $-34,000,000 | $83,000,000 | $747,000,000 | $492,000,000 |
| Change In Receivables | $156,000,000 | $534,000,000 | $493,000,000 | $1,790,000,000 |
| Changes In Account Receivables | $156,000,000 | $534,000,000 | $493,000,000 | $1,790,000,000 |
| Other Non Cash Items | $77,000,000 | $60,000,000 | $7,000,000 | $28,000,000 |
| Stock Based Compensation | $483,000,000 | $429,000,000 | $305,000,000 | $226,000,000 |
| Amortization Of Securities | $-67,000,000 | $-95,000,000 | $-61,000,000 | $31,000,000 |
| Depreciation Amortization Depletion | $215,000,000 | $189,000,000 | $621,000,000 | $348,000,000 |
| Depreciation And Amortization | $215,000,000 | $189,000,000 | $621,000,000 | $348,000,000 |
| Earnings Losses From Equity Investments | $8,000,000 | $52,000,000 | $35,000,000 | $0 |
| Net Income From Continuing Operations | $-2,822,000,000 | $-3,561,000,000 | $-4,714,000,000 | $8,362,000,000 |
| Common Stock Payments | - | $0 | $-1,153,000,000 | $-3,329,000,000 |
| Proceeds From Stock Option Exercised | - | - | $46,000,000 | $65,000,000 |
| Change In Tax Payable | - | - | $15,000,000 | $-828,000,000 |
| Change In Income Tax Payable | - | - | $15,000,000 | $-828,000,000 |
| Deferred Tax | - | - | $828,000,000 | $-559,000,000 |
| Deferred Income Tax | - | - | $828,000,000 | $-559,000,000 |